Imcivree

Setmelanotide, the active ingredient in Imcivree, is a melanocortin‑4 receptor (MC4R) agonist presented as an injectable solution for subcutaneous use. It is indicated for chronic weight management in patients with obesity linked to genetic deficiencies such as POMC, PCSK1, LEPR, Bardet‑Biedl and Alström syndromes.

GNH USA supplies Imcivree as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with distribution aligned to EU regulatory standards. The company ensures product integrity through cold‑chain logistics and provides comprehensive documentation for import and clinical use.

Imcivree targets the melanocortin pathway and is used for rare genetic forms of obesity. - Obesity due to proopiomelanocortin (POMC) deficiency: helps achieve sustained weight reduction and improved metabolic control. - Obesity due to proprotein convertase subtilisin/kexin type 1 (PCSK1) deficiency: supports long‑term weight loss and better glycaemic parameters. - Obesity due to leptin receptor (LEPR) deficiency: reduces appetite and promotes energy expenditure. - Obesity associated with Bardet‑Biedl syndrome: contributes to clinically meaningful weight decrease. - Obesity associated with Alström syndrome: assists in managing body weight and related comorbidities.

Common Side Effects: - Injection site pain or erythema. - Nausea or vomiting. - Headache. - Diarrhoea or constipation. - Hyperpigmentation of skin. Serious or Rare Side Effects: - Severe hypersensitivity reactions including anaphylaxis. - Suicidal ideation or behaviour. - Marked hyperpigmentation affecting large body areas.

Imcivree should be used under specialist supervision with attention to the following precautions. - Pregnancy: safety unknown; avoid unless benefits outweigh potential risks. - Pediatric use: limited data; restrict to approved genetic indications. - Renal impairment: monitor renal function as clearance may be reduced. - Mental health: monitor for suicidal thoughts or mood changes. - Concomitant weight‑loss therapies: assess for additive effects. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Imcivree may interact with other agents that affect appetite, metabolism or immune response. Major Interactions (Avoid): - Co‑administration with other MC4R agonists: risk of excessive appetite suppression. - Live vaccines: potential reduction in vaccine efficacy. - Strong CYP enzyme modulators: may alter drug exposure (limited data). Moderate Interactions (Monitor Closely): - Antihypertensive drugs: weight loss may lower blood pressure, requiring dose adjustment. - Antidiabetic agents: monitor glucose levels as weight reduction can affect glycaemic control.